Replies to post #123028 on Biotech Values

[genisi]

Roche was unable to shorten the treatment duration in their ACCELERATE trial. 16 weeks of treatment with SOC saw lower SVR rates and higher relapse rates. As far as I know 24 weeks of treatment is the standard.

After analyzing ACCELERATE trial data, Roche announced back in 2008 that the European Commission has approved a shortened, 16-week course of treatment with SOC for certain hepatitis C patients (genotype 2/3 who have low virus levels before starting treatment, and who show a rapid virological response:

http://www.roche.com.pk/media260608.html

This protocol is common here and partly mentioned in the US guideline:

http://www.hepatitis.va.gov/provider/guidelines/quicknotesHCV-pda-04-02.asp

I was wondering how many GT2/3 patients still get the 24 weeks course when 16 weeks should be enough for them.